Israel Henig

TL;DR: Transplant-related mortality has decreased due to improved supportive care, including better strategies to prevent severe infections and with the incorporation of reduced-intensity conditioning protocols that lowered the toxicity and allowed for transplantation in older patients, however, disease relapse and graft-versus-host disease remain the two major causes of mortality with unsatisfactory progress.

TL;DR: Oral antibiotic treatment with nonabsorbable drugs to which CRE is susceptible appears to be an effective and safe for eradication of CRE colonization and, thereby, may reduce patient- to-patient transmission and incidence of clinical infection with this difficult-to-treat organism.

TL;DR: Vorinostat for GVHD prevention is an effective strategy that should be confirmed in a randomized phase 3 study and enhanced histone (H3) acetylation in peripheral blood mononuclear cells and reduced interleukin 6 and GV HD biomarkers at day 30 post-HCT in vorInostat-treated subjects compared with similarly treated patients who did not receive vor inostat.

TL;DR: Three consecutive patients with advanced post-allo-SCT relapse, whose residual disease was eradicated following administration of daratumumab, provided on a compassionate basis are described.

TL;DR: In conclusion, post-HSCT NS usually develops concomitant to GVHD and is associated with high rates of response to therapy, although most patients were treated with a combination of immunosuppressive drugs, single-agent therapy with steroids may be sufficient in some cases.